Johnson & Johnson (NYSE:JNJ) Maintains Strong Position in Healthcare Sector

Core Viewpoint - Johnson & Johnson (JNJ) is a leading player in the healthcare sector, demonstrating strong market performance and investor confidence, with RBC Capital maintaining an "Outperform" rating and raising the price target to $255 [1][4][5] Financial Performance - From May 2025 to February 2026, JNJ's stock increased by 52%, attributed to improved earnings and product achievements [2][5] - The company's revenue grew by 3.2%, supported by better margins, innovation, and strategic evolution [2] - JNJ's current stock price is $233.39, reflecting a 1.14% increase, with a daily trading range between $230.48 and $235.20 [2] Market Position - JNJ's market capitalization is approximately $562.31 billion, with a trading volume of 1,331,327 shares [3][5] - The stock has experienced a high of $235.24 and a low of $141.50 over the past year [3] Strategic Outlook - RBC Capital's decision to raise the price target indicates confidence in JNJ's future growth prospects, driven by strategic initiatives and product innovations [4][5] - The company's effective risk management and progress in legal matters have bolstered its positive performance and investor confidence [3]